Browse articles from EyeWorld.org related to the retina. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ FDA approves IND for neuropathic pain drug ➤ Phase 2 preliminary efficacy and safety data for wet AMD treatment trial ➤ First-in-human data for DME, AMD therapy ➤ Study: Rapid eye stroke detection protocol helps prevent vision loss ➤ Enrollment complete for Phase 3 trial for sozinibercept ➤ ASCRS news and events
➤ FDA warns against copycat eye drops ➤ Generic drop receives FDA approval ➤ Topline data revealed in two presentations ➤ New 72-week data from Phase 3 RVO treatment studies ➤ First patient dosed in Phase 2/3 trial for GA treatment ➤ ASCRS news and events
➤ FDA approves first IND for RNA exon editor ➤ SPA granted for Phase 3 trial of an intravitreal implant for wet AMD ➤ Study: retinal imaging helps predict risk of developing a host of diseases ➤ European Medicines Agency recommends rejection of pegcetacoplan for GA ➤ ASCRS news and events
➤ FDA agrees to special protocol assessment for AMD clinical trial ➤ Topline data from Phase 2 trial evaluating suprachoroidal wet AMD treatment ➤ First patient dosed in Phase 1 DME treatment study ➤ Study: new gene variants contributing to glaucoma susceptibility identified ➤ ASCRS news and events
➤ FDA approves updated femtosecond laser for refractive surgery ➤ Positive topline results from Phase 3, first-in-class dry eye disease studies ➤ Rare Disease Designation granted for investigational gene therapy ➤ Positive interim data for investigational Stargardt disease treatment ➤ First patient dosed in Phase 2 trial for DME treatment ➤ Research program established to investigate whole eye transplant ➤ ASCRS news and events
In a retina session at the 2023 AAO Annual Meeting, presenters debated the pros and cons of various topics.
➤ First patient treated in Phase 2 study of investigational emulsion for glaucoma ➤ FDA issues complete response letter for dry eye drug NDA ➤ FDA meeting minutes issued for BLA submissions of ophthalmic formulation of bevacizumab ➤ Phase 1/2 trial to begin for first-in-class dry AMD therapy ➤ Company merger news ➤ ASCRS news and events
➤ World’s first whole-eye transplant ➤ Regenerative Medicine Advanced Therapy designation for investigational therapy for Leber congenital amaurosis ➤ 48-month trial data for retinal prosthesis for patients with severe atrophic AMD ➤ First patient dosed in Phase 1/2 trial for Stargardt disease gene therapy ➤ Partnership to develop molecule targeting DME ➤ ASCRS news and events
➤ 3-year efficacy and safety results of gene therapy for wet AMD reported ➤ Phase 2 trial results of gene therapy for diabetic retinopathy ➤ Phase 2 program for tracking glaucoma biomarkers begins ➤ Results from extension study of the first approved treatment for geographic atrophy ➤ Primary endpoint agreed upon for investigational oral diabetic retinopathy therapy ➤ ASCRS news and events
➤ FDA expands eye drop warning list ➤ Positive results in Phase 2a trial for new biodegradable sustained drug delivery implant ➤ Phase 2b study begins for investigational therapy for acute infectious conjunctivitis ➤ FDA approves additional treatment indication for bispecific antibody ➤ Enrollment complete for study evaluating femtosecond laser-created trabeculotomy ➤ Company to study personalized medicine for patients with wet AMD ➤ Enrollment complete for Phase 2b trial evaluating wet AMD therapy ➤ Pivotal trial for wet AMD therapy begins ➤ Survey evaluates female ophthalmologist experiences ➤ ASCRS news and events